机构：[1]Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China[2]Division of MR Research, Department of Radiology, Johns Hopkins University, Baltimore, MD 21287, USA[3]Department of Radiology, Futian Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China深圳市康宁医院深圳医学信息中心[4]Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China[5]Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China[6]Department of Epidemiology and Health Statistics, School of Public Health, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China[7]Department of Radiation Physics, Division of Radiation Oncology, The University of TexasMD Anderson Cancer Center, Houston, TX, USA[8]Department of Pathology, Johns Hopkins University, Baltimore,MD, USA
To explore the feasibility of using amide proton transfer-weighted (APTw) MRI metrics as surrogate biomarkers to identify the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM).Eighteen newly diagnosed GBM patients, who were previously scanned at 3T and had a confirmed MGMT methylation status, were retrospectively analysed. For each case, a histogram analysis in the tumour mass was performed to evaluate several quantitative APTw MRI metrics. The Mann-Whitney test was used to evaluate the difference in APTw parameters between MGMT methylated and unmethylated GBMs, and the receiver-operator-characteristic analysis was further used to assess diagnostic performance.Ten GBMs were found to harbour a methylated MGMT promoter, and eight GBMs were unmethylated. The mean, variance, 50th percentile, 90th percentile and Width10-90 APTw values were significantly higher in the MGMT unmethylated GBMs than in the MGMT methylated GBMs, with areas under the receiver-operator-characteristic curves of 0.825, 0.837, 0.850, 0856 and 0.763, respectively, for the discrimination of MGMT promoter methylation status.APTw signal metrics have the potential to serve as valuable imaging biomarkers for identifying MGMT methylation status in the GBM population.• APTw-MRI is applied to predict MGMT promoter methylation status in GBMs. • GBMs with unmethylated MGMT promoter present higher APTw-MRI than methylated GBMs. • Multiple APTw histogram metrics can identify MGMT methylation status. • Mean APTw values showed the highest diagnostic accuracy (AUC = 0.825).
基金：
This study was partially supported by grants from National Natural Science Foundation of China (81171322), Guangdong Provincial Natural Science Foundation (2014A030313271, S2012010009114),Guangdong Provincial Science and Technology Project(2014A020212726), Southern Medical University clinical research project(LC2016ZD028), and the National Institutes of Health (R01EB009731, R01CA166171).
第一作者机构：[1]Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China[2]Division of MR Research, Department of Radiology, Johns Hopkins University, Baltimore, MD 21287, USA[3]Department of Radiology, Futian Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China
通讯作者：
通讯机构：[1]Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China[2]Division of MR Research, Department of Radiology, Johns Hopkins University, Baltimore, MD 21287, USA[3]Department of Radiology, Futian Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China
推荐引用方式(GB/T 7714)：
Shanshan Jiang,Qihong Rui,Yu Wang,et al.Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.[J].EUROPEAN RADIOLOGY.2018,28(5):2115-2123.doi:10.1007/s00330-017-5182-4.
APA：
Shanshan Jiang,Qihong Rui,Yu Wang,Hye-Young Heo,Tianyu Zou...&Zhibo Wen.(2018).Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics..EUROPEAN RADIOLOGY,28,(5)
MLA：
Shanshan Jiang,et al."Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.".EUROPEAN RADIOLOGY 28..5(2018):2115-2123
医学